Dropless Pars Plana Vitrectomy Study

Description

To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.

Conditions

Rhegmatogenous Retinal Detachment

Talk to us

Study Overview

On this page

Study Details

Study overview

To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.

Dropless Pars Plana Vitrectomy Study

Dropless Pars Plana Vitrectomy Study

Condition
Rhegmatogenous Retinal Detachment
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts Eye and Ear, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Primary rhegmatogenous retinal detachment (mac-on or mac-off) requiring pars plana vitrectomy (23, 25 and 27-gauge)
  • * Need for concomitant lensectomy or cataract surgery
  • * Pars plana vitrectomy taking place more than seven days after the initial diagnosis
  • * History of any prior vitreoretinal surgery (excluding laser surgery) in surgical eye
  • * History of previous retinal detachment in surgical eye
  • * History of ocular incisional surgery within six months of surgery (excluding laser surgery) in surgical eye
  • * History of ocular laser surgery within 1 month in surgical eye
  • * History of intravitreal injection within 1 month in surgical eye
  • * Diagnosis of glaucoma or intraocular pressure more than 21 mmHg in either eye
  • * Active or chronic or recurrent uncontrolled ocular or systemic disease
  • * Active or history of chronic or recurrent inflammatory eye disease
  • * Previous history of steroid response
  • * Current treatment with oral, topical, or intravitreal corticosteroids
  • * Presence of proliferative vitreoretinopathy at the time of diagnosis
  • * Presence of giant retinal tear at the time of diagnosis
  • * Diagnosis of proliferative diabetic retinopathy
  • * Anterior chamber inflammation on presentation in either eye
  • * Signs of ocular infection at presentation in either eye
  • * Acute external ocular infections
  • * Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
  • * Inability to use or apply topical eye drops
  • * Requirement for silicone oil as a tamponade agent
  • * Individuals with impaired decision-making capacity
  • * Non-English-speaking subjects

Ages Eligible for Study

40 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Massachusetts Eye and Ear Infirmary,

Nimesh A. Patel, MD, PRINCIPAL_INVESTIGATOR, Massachusetts Eye and Ear

Study Record Dates

2026-01-30